• Globe Newswire

Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate

Globenewswire -

• Globe Newswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Globenewswire -

• Globe Newswire

Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness